OraSure Technologies (NASDAQ:OSUR) and Bio-Rad Laboratories (NYSE:BIO) Head to Head Review

OraSure Technologies (NASDAQ:OSUR) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Volatility & Risk

OraSure Technologies has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

Earnings & Valuation

This table compares OraSure Technologies and Bio-Rad Laboratories”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02 million	1.80	-$68.73 million	($1.04)	-2.89
Bio-Rad Laboratories	$2.59 billion	2.92	$759.90 million	$6.07	46.52

Bio-Rad Laboratories has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OraSure Technologies and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-66.42%	-18.57%	-15.71%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

Institutional & Insider Ownership

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 3.9% of OraSure Technologies shares are held by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for OraSure Technologies and Bio-Rad Laboratories, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1	1	0	0	1.50
Bio-Rad Laboratories	1	3	1	0	2.00

OraSure Technologies presently has a consensus target price of $3.00, suggesting a potential downside of 0.33%. Bio-Rad Laboratories has a consensus target price of $303.33, suggesting a potential upside of 7.41%. Given Bio-Rad Laboratories’ stronger consensus rating and higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than OraSure Technologies.

Summary

Bio-Rad Laboratories beats OraSure Technologies on 13 of the 14 factors compared between the two stocks.

About OraSure Technologies

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.